On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
30 years of research has highlighted the crucial role of oestrogen in the disease profile of women with psychotic disorders. However, we have not translated this knowledge into tailored treatment strategies. I will present the work conducted during my PhD, which focused on understanding the impact of sex and sex hormones, particularly oestrogen, on the disease trajectory and treatment of psychotic disorders. In the first part, I will explore the interplay between sex, oestrogen, and current treatment strategies for psychosis, emphasising the links between hyperprolactinaemia and clinical outcomes, as well as the influence of sex on the effectiveness and tolerability of antipsychotics. In the second part, I will discuss how we might harness the beneficial effects of oestrogen to optimise treatment strategies, drawing on evidence from clinical trials and birth cohort studies. Lastly, I will provide a brief overview of our current efforts to better understand the impact of sex and sex hormones on the disease course of schizophrenia-spectrum disorders, with the aim of advancing care.
This seminar is hosted in person and online, to join via Zoom, please use the details below:
zoom.us/j/93598736019?pwd=tHJ65nmXIrmYTUhi7YRbbdlnyi5Ie6.1
Meeting ID: 935 9873 6019
Passcode: 897963
